Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Key HIV stat over 70% leaves BofA siding with Gilead

8 August 2026 · By · Wire by Fusion42

Published

8 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at thestreet.com →

◆ Verified

Fusion42 · 28 August 2026 · Fusion42 review

Bank of America maintained its Buy rating on Gilead Sciences after strong Q2 results and highlighted that over 70% persistence in the HIV prevention drug Yeztugo supports a large commercial opportunity, contributing to raised sales guidance for 2026.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You now have clear evidence that Gilead's HIV prevention drug maintains high patient persistence, opening a bigger revenue runway for long-acting PrEP treatments this year. This is your moment to push into or expand within HIV prevention where durable patient use drives steady income.

◆ Coverage

1 source · 8 Aug 2026

◆ Related on Wire

◆ Topics

Biotechgileadhiv-preventionprEPbiotechdrug-salespersistence